Supplementary Table from Osimertinib plus Selumetinib in EGFR-Mutated Non–Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)
posted on 2023-04-01, 00:01authored byJames Chih-Hsin Yang, Yuichiro Ohe, Chao-Hua Chiu, Xiaoling Ou, Mireille Cantarini, Pasi A. Jänne, Ryan J. Hartmaier, Myung Ju Ahn
Supplementary Table from Osimertinib plus Selumetinib in EGFR-Mutated Non–Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)
Funding
AstraZeneca
Merck Sharp & Dohme Corp.
Merck & Co., Inc.
Good Publications Practice
History
ARTICLE ABSTRACT
MEK/ERK inhibition can overcome acquired resistance to osimertinib in preclinical models. Osimertinib [EGFR–tyrosine kinase inhibitor (TKI)] plus selumetinib (MEK1/2 inhibitor) was assessed in the global TATTON study.
This multicenter, open-label, phase Ib study expansion cohort enrolled patients (aged ≥18 years) with MET-negative, EGFRm advanced NSCLC who had progressed on EGFR-TKIs. Patients were assigned to one of two cohorts by prior first- or second-generation or T790M-directed EGFR-TKI and received osimertinib 80 mg every day and intermittent selumetinib 75 mg twice a day orally. Safety and tolerability (primary objective) and antitumor activity determined by objective response rate (ORR), and progression-free survival (PFS) using RECIST v1.1 were assessed. Data cutoff: March 4, 2020.
Forty-seven patients received treatment (prior first- or second-generation EGFR-TKI, n = 12; prior T790M-directed EGFR-TKI, n = 35). Forty-four (94%) patients were Asian; 30 (64%) had baseline exon 19 deletion. Most common AEs were diarrhea (89%), decreased appetite (40%), and stomatitis (32%); 11/47 patients (23%) had an AE Grade ≥3 possibly causally selumetinib-related. ORR was 66.7% [95% confidence interval (CI), 34.9–90.1] in the prior first- or second-generation EGFR-TKI group, 22.9% (95% CI, 10.4–40.1) in the prior T790M-directed EGFR-TKI group, and 34.0% (95% CI, 20.9–49.3) overall; median PFS was 15.0 (95% CI, 2.7–33.0), 2.8 (95% CI, 1.6–5.5), and 4.2 months (95% CI, 2.7–7.2), respectively.
In this small study, AEs and tolerability of osimertinib plus selumetinib were as expected, on the basis of previous studies. The combination demonstrated antitumor activity supportive of further investigation in patients with MET-negative, EGFRm advanced NSCLC who had progressed on a previous EGFR-TKI.